Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100071
Funder
Australian Research Council
Funding Amount
$290,000.00
Summary
Chemi–biology computational platform for lead discovery in infectious disease. A challenge in fighting infectious disease is in finding new bioactive compounds. This facility will provide a high performance computational environment designed to accelerate the discovery of quality compounds for use in anti-infective medicine.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE130100164
Funder
Australian Research Council
Funding Amount
$310,000.00
Summary
A facility for ex-vivo molecular imaging. The facility will allow a consortium of Australian researchers to create an integrated facility for imaging biological receptors in tissue, bringing together laboratory, radiochemistry and imaging expertise. Digital data at each site will be able to be viewed and analysed remotely.
Liposaccharide based peptide and vaccine delivery systems: improving the bioavailability and immunogenicity of Luteinizing Hormone-Releasing Hormone. This project aims to develop new lipid- and sugar-based drug delivery systems for Luteinizing-hormone-releasing hormone (LHRH), a hormone which regulates the level of enzymes involved in fertility conditions and prostate cancers. This technology could be extended to significantly increase the number of drugs available on the market, such as peptide ....Liposaccharide based peptide and vaccine delivery systems: improving the bioavailability and immunogenicity of Luteinizing Hormone-Releasing Hormone. This project aims to develop new lipid- and sugar-based drug delivery systems for Luteinizing-hormone-releasing hormone (LHRH), a hormone which regulates the level of enzymes involved in fertility conditions and prostate cancers. This technology could be extended to significantly increase the number of drugs available on the market, such as peptide drugs and vaccines.Read moreRead less
Barriers and pathways to development of Indigenous traditional medicines. This project aims to explore how Australian regulatory systems can better support Aboriginal and Torres Strait Islander Traditional Knowledge (TK) holders to commercialise their traditional medicines. Focusing on the mudjala plant and working with the Kimberley’s Nyikina people, the project should generate new anthropological methods for documenting TK related to traditional medicine, new models for regulating traditional ....Barriers and pathways to development of Indigenous traditional medicines. This project aims to explore how Australian regulatory systems can better support Aboriginal and Torres Strait Islander Traditional Knowledge (TK) holders to commercialise their traditional medicines. Focusing on the mudjala plant and working with the Kimberley’s Nyikina people, the project should generate new anthropological methods for documenting TK related to traditional medicine, new models for regulating traditional medicinal products, and pharmacological insights into traditional methods of activating the plant. Additional expected outcomes include unlocking the significant, untapped potential for Indigenous Australians to benefit from the development of traditional medicine products regulated by the Therapeutic Goods Administration.Read moreRead less
Innovations in peptide-based drug design. This project will aim to develop new types of drugs that fill a gap between existing small molecule drugs, which are relatively inexpensive and stable, but often have side-effects, and biologics which are very expensive and require injection. Our new generation of peptide-based drugs promise to be applicable to diseases that are not treatable by current drugs.
Development of effective peptide-based drugs. There is huge interest in the development of bioactive peptides and proteins for the treatment of a wide range of diseases. The aim of this research project is to develop potent and effective peptide-based drugs that are able to resist the body's natural degradation pathways so that they can reach their biological target and act as effective drugs.
Advancing hybrid imaging with magnetic resonance imaging and positron emission tomography (MRI-PET). This project aims to increase the utility, accessibility, cost-effectiveness and accuracy of magnetic resonance imaging and positron emission tomography (MRI-PET) hybrid imaging technology for brain tumour imaging. This project will develop new contrast agents, better ways of measuring their uptake including a new high sensitivity MRI-PET head coil and methods for predicting tumour progression us ....Advancing hybrid imaging with magnetic resonance imaging and positron emission tomography (MRI-PET). This project aims to increase the utility, accessibility, cost-effectiveness and accuracy of magnetic resonance imaging and positron emission tomography (MRI-PET) hybrid imaging technology for brain tumour imaging. This project will develop new contrast agents, better ways of measuring their uptake including a new high sensitivity MRI-PET head coil and methods for predicting tumour progression using imaging information.Read moreRead less
Development of a multicomponent delivery system for oligonucleotides. Gene therapy has the ability to prevent faulty genes from causing disease, however the ability to deliver genetic material into specific cells remains a major barrier. Our research will overcome this hurdle by generating systems that are superior to existing technologies.
Poly(amino acids) as immune stimulators. This project aims to develop nanoparticles built from natural hydrophobic amino acids as an immune stimulatory delivery system for peptide antigens. Currently available immune stimulants (adjuvants) are often toxic and/or are poorly chemically defined fragments of bacteria or toxins and vary from batch-to-batch. New adjuvants are in high demand; especially to facilitate the use of optimal, but weakly immunogenic, peptide antigens. It is expected that the ....Poly(amino acids) as immune stimulators. This project aims to develop nanoparticles built from natural hydrophobic amino acids as an immune stimulatory delivery system for peptide antigens. Currently available immune stimulants (adjuvants) are often toxic and/or are poorly chemically defined fragments of bacteria or toxins and vary from batch-to-batch. New adjuvants are in high demand; especially to facilitate the use of optimal, but weakly immunogenic, peptide antigens. It is expected that the proposed project will develop a novel efficient, safe and notably biodegradable self-adjuvanting delivery system that can be fully customised to match an antigen of choice. This foundational research should provide important advances for commercial immune stimulatory applications.Read moreRead less
Developing a paradigm shift in new pharmaceutical and agrochemical design. This project will provide a paradigm shift in the design of new medicines and farming chemicals. The outcome of this research will be the efficient generation of diverse chemicals having real possibilities to improve global health and food security in the future.